Brief: Shanghai Junshi Biosciences Says Acceptance Of Supplemental New Drug Application For Toripalimab
11/07/2023 16:00
July 11 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR
TORIPALIMAB
AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Source text for Eikon: ID:
Further company coverage: 688180.SS
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab